Dearborn Partners LLC Makes New Investment in Stryker Corporation $SYK

Dearborn Partners LLC purchased a new stake in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 65,038 shares of the medical technology company’s stock, valued at approximately $20,476,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Norges Bank bought a new position in shares of Stryker in the fourth quarter worth approximately $1,822,272,000. Bank of America Corp DE bought a new stake in Stryker during the second quarter valued at approximately $1,404,284,000. Auto Owners Insurance Co lifted its position in Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares during the last quarter. Legal & General Group Plc purchased a new position in Stryker in the 2nd quarter worth approximately $707,212,000. Finally, Jupiter Topco LLC bought a new position in shares of Stryker in the 2nd quarter worth $681,581,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $322.20 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The business’s 50 day simple moving average is $328.64 and its two-hundred day simple moving average is $331.47. The stock has a market capitalization of $123.58 billion, a P/E ratio of 33.39, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter last year, the business earned $3.13 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Analyst Ratings Changes

SYK has been the topic of several research reports. Needham & Company LLC lowered their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Evercore set a $350.00 target price on shares of Stryker in a research report on Monday, July 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Robert W. Baird set a $385.00 price target on Stryker in a research note on Friday, May 1st. Finally, Citizens Jmp cut their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the transaction, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 in the last 90 days. Company insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.